Aviceda's geographic atrophy drug fails mid-stage study. Can it do better in Phase 3?

Aviceda Therapeutics is pushing forward with Phase 3 plans for its experimental eye drug despite failing a Phase 2b study in geographic atrophy. The mid-stage trial compared Aviceda’s AVD-104 to Astellas’ drug Izervay in patients ...